Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held by Akebia Therapeutics, Inc. on June 17, 2026. The filing details the outcomes of five proposals submitted to security holders, including director elections, charter amendments, and executive compensation votes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.
Material Changes and Voting Results
- Director Elections (Proposal 1): Stockholders elected Adrian Adams, Michael Rogers, and LeAnne M. Zumwalt as Class III directors. Each received significant support, though a notable portion of votes were withheld (approximately 29% to 32% withheld).
- Share Increase Amendment (Proposal 2): Stockholders approved an amendment to increase authorized capital stock from 375,000,000 to 525,000,000 shares and authorized common stock from 350,000,000 to 500,000,000 shares. The vote was split, with 102,504,108 votes for and 88,853,129 votes against.
- Executive Compensation Ratification (Proposal 3): Stockholders approved the compensation of named executive officers on a non-binding advisory basis. The vote was divided, with 89,838,833 votes for and 51,140,010 votes against.
- Compensation Vote Frequency (Proposal 4): Stockholders recommended annual advisory votes on executive compensation. 112,927,161 votes favored a 1-year frequency, compared to 20,605,688 for a 3-year frequency.
- Auditor Ratification (Proposal 5): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 173,306,165 votes for.
Guidance, Outlook, and Management Commentary
Following the vote on Proposal 4, the Board of Directors intends to hold an advisory vote on executive compensation on an annual basis until the next required frequency vote, which must occur at least once every six years. The Company filed the Certificate of Amendment to effect the share increase with the Delaware Secretary of State on June 18, 2026.
Important Facts for Investor Verification
- Verify the impact of the increased authorized share count (525,000,000 total) on potential future dilution.
- Review the significant number of votes withheld on director elections and votes against the share increase and executive compensation proposals to gauge shareholder sentiment.
- Confirm the Board's commitment to annual executive compensation advisory votes as a governance standard.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial health metrics.